ARCHIVE SEARCH
      -OR-  
 
  NEWS CHANNELS
Fitness News
 > Asthma Allergy News
Diabetes News
Women's Health News
Men's Health News

  MY NEWS
Personal Archive
My Account

  ABOUT THIS NEWSFEED
About Us
Advertise With Us
Feed Your Site
Contact Us


Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

 
FDA Approves Opsumit for Pulmonary Arterial Hypertension
Opsumit (macitentan) relaxes the pulmonary arteries, decreasing blood pressure in the vessels

WEDNESDAY, Oct. 23 (HealthDay News) -- Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension.

Opsumit relaxes the pulmonary arteries, decreasing blood pressure in the vessels, the FDA said in a news release.

The drug's safety and effectiveness were evaluated in clinical studies involving 742 people. The medication was found effective in "delaying disease progression," the agency said.

The most common side effects included anemia, nasopharyngitis, bronchitis, headache, flu, and urinary tract infection.

Opsumit's label includes a boxed warning that the medication could harm a developing fetus, so the drug should not be taken by pregnant women, the FDA said.

The drug is marketed by Actelion Pharmaceuticals U.S., based in San Francisco.

More Information



Health News Copyright © 2013 HealthDay. All rights reserved.


Back to Top Stories
  GOOGLE ADS